Short answer
Ginkgo Bioworks Holdings, Inc. (DNA) filed its Q2 2026 10-Q quarterly report on Aug 6, 2026 for the quarter ended Jun 30, 2026. Quarterly revenue was $20M (down 59.4% year over year) with net income of −$47M.
Q2 2026 key financials · XBRL
- Revenue
- $20M
- −59.4% YoY · +3.5% QoQ
- Net income
- −$47M
- +22.5% YoY · +43.4% QoQ
- Operating margin
- -290.5%
- EPS (diluted)
- −$0.74
- +32.1% YoY · +46.8% QoQ
Source: XBRL data from the Ginkgo Bioworks Holdings, Inc. (DNA) Q2 2026 10-Q on SEC EDGAR. USD.
Ginkgo Bioworks Holdings, Inc. Q2 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $20.2M, down $19.0M YoY from $39.1M, driven by reduced large-enterprise programs
- Operating margin -290.5% vs -148.7% YoY, based on operating losses of $58.5M and $58.2M
- R&D expenses $46.2M, down $7.2M YoY; G&A expenses $30.8M, down $4.2M
- Interest income $3.2M vs $6.1M, reflecting lower average cash balances
- 2026 R&D and G&A expenses expected consistent or declining; tools investment could increase R&D
Risk Factors
- No risk-factors section provided; supplied text contains Items 2–6 and signatures only
- Newly disclosed transaction: Tower Biosecurity stock purchase agreement dated February 26, 2026
- Regulatory, legal, liquidity, competitive, and market risks not assessable from provided text
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Ginkgo Bioworks Holdings, Inc. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.